Form 483

Cosmecca Korea Co., Ltd. Form 483, 2017-09-22

FDA issued a Form 483 to Cosmecca Korea Co., Ltd. on 2017-09-22 with 10 public-safe observations.

483· Form 483 issuedHuman Drugs10 observations

Cosmecca Korea Co., Ltd. · Eumseong, Korea (the Republic of) · Issued September 22, 2017

Overview

  • 10 public-safe observations are available for this inspection.
  • 10 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

22 Sep 2017
21 CFR 211.110(a)

Written in-process control procedures

Cited by Lucila B Nwatu

22 Sep 2017
21 CFR 211.113(a)

Procedures for non-sterile drug products

Cited by Lucila B Nwatu

22 Sep 2017
21 CFR 211.160(a)

Following/documenting laboratory controls

Cited by Lucila B Nwatu

22 Sep 2017
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Lucila B Nwatu

22 Sep 2017
21 CFR 211.188

Prepared for each batch, include complete information

Cited by Lucila B Nwatu

Inspected site

CKCosmecca Korea Co., Ltd.Eumseong, Korea (the Republic of)

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.110(a)Cited across public-safe Form 483 observations1x
21 CFR 211.113(a)Cited across public-safe Form 483 observations1x
21 CFR 211.160(a)Cited across public-safe Form 483 observations1x
21 CFR 211.160(b)Cited across public-safe Form 483 observations1x
21 CFR 211.188Cited across public-safe Form 483 observations1x
21 CFR 211.194(a)Cited across public-safe Form 483 observations1x
21 CFR 211.194(a)(2)Cited across public-safe Form 483 observations1x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x
21 CFR 211.63Cited across public-safe Form 483 observations1x
21 CFR 211.68(b)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 10 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere